Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.

Last updated: November 16, 2023
Sponsor: University Hospital Augsburg
Overall Status: Active - Recruiting

Phase

N/A

Condition

Metastatic Cancer

Neuroblastoma

Neoplasm Metastasis

Treatment

N/A

Clinical Study ID

NCT05245136
N67
  • Ages > 18
  • All Genders

Study Summary

A prospective observational trial of patients with metastatic cancer of various entities which aims at both clarifying the significance of liquid biopsy and establishing a foundation for translational research.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Written informed consent
  • Age ≥ 18 years
  • Histopathologically confirmed metastatic or locally advanced cancer
  • No curative treatment options, except for germ cell tumors
  • Written Agreement to be followed up at Augsburg University Medical Center
  • Signed written informed consent for the Biobank Augsburg (Biobank-A)
  • Willing to undergo treatment according to standard of care
  • Availability or anticipated availability of tumor tissue at time point of inclusion
  • Anticipated life expectancy of at least 3 months at time point of trial inclusion

Exclusion

Exclusion Criteria:

  • Psychological condition that would preclude informed consent
  • Additional tumor treatment between acquisition of tumor tissue and trial inclusion

Study Design

Total Participants: 3000
Study Start date:
March 29, 2021
Estimated Completion Date:
April 30, 2025

Study Description

ALPS is a prospective observational trial to assess liquid biopsy as diagnostic tool in patients with various metastatic neoplasms. Liquid biopsy will be correlated not only with the tissue biopsy, but also to imaging modalities and classical tumor markers. In addition, the study aims to investigate clonal heterogeneity and evolution of different cancers during patient treatment courses. A third aspect of the study is to survey and assess patients' knowledge about biomarkers and personalized medicine in general and about liquid biopsy as a new diagnostic tool.

Connect with a study center

  • University Hospital Augsburg

    Augsburg, Bavaria 86156
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.